Understanding fibromyalgia and the search for better treatments
Fibromyalgia is a chronic pain condition that affects millions worldwide. People with fibromyalgia often live with widespread pain, fatigue, sleep problems, and difficulty concentrating. While medications and therapy can help, many patients continue to struggle, making it important to explore new treatments. A new study surrounding repetitive transcranial magnetic stimulation (rTMS) reveals new findings.
One option being studied is repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique. rTMS uses magnetic pulses applied to specific brain regions, and it has already been approved for conditions like depression. Researchers are now testing whether this therapy could also help people with fibromyalgia.
What this pilot study explored
A team of scientists in Germany recently carried out a pilot trial on repetitive transcranial magnetic stimulation and fibromyalgia. Twenty-seven women diagnosed with fibromyalgia participated. They were randomly assigned to receive either active rTMS or sham (placebo) stimulation targeting the left dorsolateral prefrontal cortex (DLPFC), an area of the brain involved in mood regulation and pain processing.
Over two weeks, patients underwent ten sessions of either active or sham rTMS. Researchers also used advanced brain imaging before treatment, after treatment, and again at follow-up. Alongside imaging, participants completed questionnaires about pain, mood, anxiety, and quality
Key findings from the trial
The results showed that both groups—active and sham—experienced some symptom improvement, suggesting a strong placebo effect. However, the active rTMS group showed unique brain changes:
- Increased connectivity in the brain: Imaging revealed greater communication between the prefrontal cortex and the cerebellum in patients who responded well to rTMS.
- White matter changes: Measures of fractional anisotropy (FA), which reflect the integrity of white matter tracts in the brain, increased in specific regions after rTMS.
- Neurochemical shifts: While not statistically strong, there was a trend toward reduced glutamate/glutamine (Glx) levels across all patients, hinting at possible changes in neurotransmitter balance.
These brain-level changes suggest that rTMS may alter pain-related networks, even if clinical improvements weren’t dramatically different from placebo in this small sample.
Why this matters
Fibromyalgia remains a challenging condition to treat. The findings highlight that even if symptom relief is modest, repetitive transcranial magnetic stimulation and fibromyalgia research is beginning to uncover how brain circuits may adapt to neuromodulation. Larger trials with longer treatment periods are needed to see whether these brain changes can translate into more consistent clinical benefits.
For patients, this study represents cautious optimism. While rTMS is not yet a standard therapy for fibromyalgia, these early results pave the way for new approaches that could improve quality of life for people living with chronic pain.
Final thoughts
The growing interest in neuromodulation underscores a shift in psychiatry and pain medicine: treatments are moving beyond medication alone and into the realm of brain-based interventions. Repetitive transcranial magnetic stimulation continues to be a promising candidate for conditions like depression, PTSD, and now potentially fibromyalgia. With larger and longer-term studies, rTMS could become part of the toolkit for managing chronic pain syndromes.
Learn more at https://interventionalpsychiatry.org/
References
- Ackermann L, Zeller D, Odorfer T, et al. Effect of repetitive transcranial magnetic stimulation on the symptoms and brain imaging in patients with fibromyalgia syndrome: A randomized controlled pilot trial. Adv Ther. 2025. https://pubmed.ncbi.nlm.nih.gov/40884738/
- O’Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev. 2018. https://pubmed.ncbi.nlm.nih.gov/29547226/